Chart-Typ:
Zeitraum:
| Innocan Pharma Corporation: Valitic Surpasses 2 Million Trusted Customers, Marking a Major Milestone in Its Consumer Wellness Growth | The rapidly growing skincare brand continues to strengthen its position in the U.S. beauty market through innovation, quality, and customer trust.HERZLIYA, Israel and CALGARY, AB, July 29... ► Artikel lesen |
| Innocan Pharma Corporation: Innocan Pharma Posts Strong Q1 2026 Results*, With Revenue Surging 29.7% to US$6.47M | HERZLIYA, Israel and CALGARY, AB, May 27, 2026 /PRNewswire/ -- Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTC: INNPF) (the "Company" or "Innocan"), a pharmaceutical technology company... ► Artikel lesen |
| Innocan Pharma Corporation: Innocan Pharma Posts Strong Q1 2026 Results, With Revenue Surging 29.7% to US$6.47M | HERZLIYA, Israel and CALGARY, AB, May 27, 2026 /PRNewswire/ -- Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTC: INNPF) (the "Company" or "Innocan"), a pharmaceutical... ► Artikel lesen |
| Inovio Pharmaceuticals, Inc.: INOVIO Announces Pricing of $20.0 Million Public Offering | PLYMOUTH MEETING, Pa., July 29, 2026 /PRNewswire/ -- INOVIO Pharmaceuticals, Inc. (Nasdaq: INO), a biotechnology company focused on developing and commercializing... ► Artikel lesen |
| Inovio Pharmaceuticals, Inc.: INOVIO Announces Proposed Public Offering | PLYMOUTH MEETING, Pa., July 29, 2026 /PRNewswire/ -- INOVIO Pharmaceuticals, Inc. (Nasdaq: INO), a biotechnology company focused on developing and commercializing... ► Artikel lesen |
| INOVIO Pharmaceuticals, Inc.: Positive Topline Results from a Phase 3 Trial for VGX-3100 in Cervical Dysplasia Patients Announced by ApolloBio, INOVIO's Partner in China | Results provide important clinical evidence to support ApolloBio's future regulatory submission in China of VGX-3100, INOVIO's DNA immunotherapy candidate
ApolloBio's... ► Artikel lesen |
| InflaRx N.V.: InflaRx Assessing Feasibility of Broadened Strategy for ANCA-Associated Vasculitis in Europe Following EMA Recommendation on Tavneos | InflaRx intends to engage with EMA regarding both vilobelimab and izicopan to evaluate the regulatory path to approval in ANCA-associated vasculitis (AAV)The Company is assessing the most efficient... ► Artikel lesen |
| InflaRx wird zur Biotech-Wette | Die InflaRx-Aktie hat in den vergangenen Wochen wieder deutlich mehr Aufmerksamkeit auf sich gezogen. Nach einer längeren Durststrecke sorgen neue Fantasie rund um die Pipeline, frisches Kapital und... ► Artikel lesen |
| InflaRx schließt Kapitalerhöhung über 150 Millionen Dollar ab | Wie angekündigt hat InflaRx die Platzierung von 75 Millionen Stammaktien zu je 2,00 US-Dollar abgeschlossen. Der Bruttoerlös beläuft sich nach Angaben des Jenaer Biotechnologie-Unternehmens auf 150... ► Artikel lesen |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu JYONG BIOTECH LTD finden Sie auf Wallstreet Online.